Login to Your Account



Other News To Note


Tuesday, March 1, 2011
Santaris Pharma A/S, of Hoersholm, Denmark, obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for treating cardiovascular disorders. Financial terms were not disclosed. Santaris intends to use its Locked Nucleic Acid platform to develop a LNA-based drug targeting miR-33.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription